Literature DB >> 11972444

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

L DiAnne Bradford1.   

Abstract

Over 40 cytochrome P450 (CYP) 2D6 allelic variants have been discovered thus far. The alleles may be classified on the basis of the level of activity for which they encode CYP2D6 enzymes, into functional, non-functional and reduced function groups. CYP2D6 allele frequency is known to vary amongst racial/ethnic groups. Generally, for European Caucasians and their descendants, the functional group of alleles are predominant, with a frequency of 71%. Non-functional alleles represent 26% of the variability, mainly CYP2D6*4. In Asians and their close descendants, functional alleles represent only ~ 50% of the frequency of CYP2D6 alleles. Asians and Pacific Islanders have a high frequency (median = 41%) of a reduced function allele, CYP2D6*10, contributing to the population shift to the right of metabolic rates indicating slower metabolism. Information concerning Amerindians from North (Canada), Central and South America indicate comparatively low frequencies of CYP2D6*10, perhaps a "founders" effect. The frequency of functional alleles in Africans and African Americans is also about 50%. Both Africans and African Americans have reduced function alleles representing 35% of allele variation, mainly CYP2D6*17. African Americans, however, have more than twice the median frequency of nonfunctional alleles compared with Africans (14.5% vs 6.3%). Non-functional and reduced function alleles represent about 50% of allele frequency in Black populations but a much greater variety than carried in Asians. Since alleles which encode for no or reduced functioning clearly affect metabolic activity of drugs mediated by CYP2D6, studies are needed in populations in which these alleles play a major role in order to assure optimal dosing recommendations are based on empirical pharmacogenetics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972444     DOI: 10.1517/14622416.3.2.229

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  187 in total

1.  Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.

Authors:  Masato Taguchi; Takashi Nozawa; Tomoki Kameyama; Hiroshi Inoue; Chihiro Takesono; Akiko Mizukami; Yukiya Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

Review 2.  Mechanisms of resistance to hormonal treatment in breast cancer.

Authors:  P Eroles; A Bosch; B Bermejo; A Lluch
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

3.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Authors:  Stuart A Scott; Rame Khasawneh; Inga Peter; Ruth Kornreich; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

4.  Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.

Authors:  Mariana Cherner; Chad Bousman; Ian Everall; Daniel Barron; Scott Letendre; Florin Vaida; J Hampton Atkinson; Robert Heaton; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2010-08-23       Impact factor: 2.892

Review 5.  Pharmacogenetics and individualizing drug treatment during pregnancy.

Authors:  David M Haas
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

Review 6.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

Review 7.  Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.

Authors:  Christine M Walko; Howard McLeod
Journal:  Nat Clin Pract Oncol       Date:  2009-01-27

8.  Three new alternative splicing variants of human cytochrome P450 2D6 mRNA in human extratumoral liver tissue.

Authors:  Jian Zhuge; Ying-Nian Yu
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

9.  Population pharmacokinetics of bisoprolol in patients with chronic heart failure.

Authors:  Valentina N Nikolic; Tatjana Jevtovic-Stoimenov; Radmila Velickovic-Radovanović; Stevan Ilic; Marina Deljanin-Ilic; Dragan Marinkovic; Svetlana Apostolović; Dragana Stanojevic; Slavoljub Zivanovic; Nikola Stefanovic; Srdjan Pesic; Dejana Ruzic Zecevic; Jasmina R Milovanovic; Slobodan M Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2012-10-24       Impact factor: 2.953

10.  Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?

Authors:  David M Haas; Mary DʼAlton
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.